Beam Therapeutics (BEAM) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BEAM Stock Forecast

Beam Therapeutics stock forecast is as follows: an average price target of $55.00 (represents a 89.59% upside from BEAM’s last price of $29.01) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

BEAM Price Target

The average price target for Beam Therapeutics (BEAM) is $55.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $69.00 to $39.00. This represents a potential 89.59% upside from BEAM's last price of $29.01.

BEAM Analyst Ratings

Buy

According to 7 Wall Street analysts, Beam Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BEAM stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Beam Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 06, 2024	Rick Bienkowski	Leerink Partners	$39.00	$24.34	60.26%	34.44%
Nov 05, 2024	Kostas Biliouris	BMO Capital	$57.00	$24.34	134.23%	96.48%
Sep 11, 2024	Benjamin Burnett	Stifel Nicolaus	$69.00	$23.34	195.69%	137.85%
Feb 01, 2023		Cantor Fitzgerald	$62.00	$43.45	42.69%	113.72%
Dec 20, 2022	Kostas Biliouris	BMO Capital	$66.00	$41.59	58.69%	127.51%
Dec 13, 2022		Citigroup	$62.00	$48.19	28.66%	113.72%
Apr 28, 2022		Credit Suisse	$62.00	$39.83	55.66%	113.72%

The latest Beam Therapeutics stock forecast, released on Nov 06, 2024 by Rick Bienkowski from Leerink Partners, set a price target of $39.00, which represents a 60.26% increase from the stock price at the time of the forecast ($24.34), and a 34.44% increase from BEAM last price ($29.01).

Beam Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	3
Avg Price Target	-	$48.00	$55.00
Last Closing Price	$29.01	$29.01	$29.01
Upside/Downside	-100.00%	65.46%	89.59%

In the current month, the average price target of Beam Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Beam Therapeutics's last price of $29.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 06, 2024	Leerink Partners		Outperform	Upgrade
Nov 05, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 11, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Aug 22, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Jul 23, 2024	H.C. Wainwright		Buy	Initialise
Apr 02, 2024	Citigroup	Buy	Buy	Hold
Mar 27, 2024	BMO Capital	Underperform	Underperform	Hold
Mar 27, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Sep 05, 2023	William Blair	Outperform	Outperform	Hold
Aug 09, 2023	Credit Suisse	Neutral	Neutral	Hold
Feb 01, 2023	Cantor Fitzgerald		Overweight	Initialise
Dec 20, 2022	BMO Capital	Market Perform	Outperform	Upgrade
Dec 13, 2022	Citigroup		Buy	Initialise
Jun 17, 2022	BMO Capital		Market Perform	Initialise
Apr 28, 2022	Credit Suisse		Neutral	Initialise

Beam Therapeutics's last stock rating was published by Leerink Partners on Nov 06, 2024. The company Upgrade its BEAM rating from "null" to "Outperform".

Beam Therapeutics Financial Forecast

Beam Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.19M	$20.12M	$24.21M	$20.04M	$15.80M	$16.65M	$8.43M	$51.07M	$763.00K	$6.00K	$6.00K	$6.00K	$6.00K	$6.00K	$6.00K
Avg Forecast	$42.67M	$37.78M	$33.45M	$29.62M	$14.14M	$14.26M	$14.11M	$14.10M	$15.88M	$14.52M	$14.18M	$17.09M	$18.67M	$17.09M	$17.32M	$15.61M	$12.71M	$7.15M	$8.39M	$44.14M	$8.56M	$1.07M	$8.34M	$2.00K	$2.00K	$1.50K	$2.00K	$4.51K
High Forecast	$88.56M	$78.41M	$69.43M	$61.47M	$29.36M	$29.60M	$29.30M	$23.02M	$36.21M	$14.79M	$14.18M	$17.09M	$27.59M	$17.28M	$35.95M	$32.40M	$26.39M	$7.15M	$8.39M	$44.14M	$8.56M	$1.07M	$8.34M	$2.00K	$2.00K	$1.50K	$2.00K	$5.41K
Low Forecast	$14.44M	$12.78M	$11.32M	$10.02M	$4.79M	$4.83M	$4.78M	$4.60M	$4.36M	$14.24M	$14.18M	$17.09M	$13.24M	$16.90M	$5.86M	$5.28M	$4.30M	$7.15M	$8.39M	$44.14M	$8.56M	$1.07M	$8.34M	$2.00K	$2.00K	$1.50K	$2.00K	$3.61K
# Analysts	4	4	4	4	3	3	3	5	9	4	5	4	8	4	5	4	4	3	4	3	14	8	9	15	10	16	8	17
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.16%	1.55%	1.58%	2.21%	1.98%	0.19%	5.96%	0.71%	0.00%	3.00%	3.00%	4.00%	3.00%	1.33%

Beam Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $18.67M, with a low forecast of $13.24M, and a high forecast of $27.59M. BEAM's average Quarter revenue forecast represents a 8.61% increase compared to the company's last Quarter revenue of $17.19M (Sep 23).

Beam Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	9	4	5	4	8	4	5	4	4	3	4	3	14	8	9	15	10	16	8	17
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-107.75M	$-109.57M	$-91.44M	$-133.01M	$-95.96M	$-89.92M	$-79.28M	$-62.07M	$-26.37M	$-74.58M	$-200.16M	$-94.19M	$-33.23M	$-33.07M	$-29.36M
Avg Forecast	$-37.67M	$-33.35M	$-29.53M	$-26.15M	$-12.49M	$-12.59M	$-12.46M	$-12.44M	$-14.02M	$-12.81M	$-12.51M	$-70.45M	$-16.49M	$-15.09M	$-15.29M	$-75.35M	$-73.58M	$-6.31M	$-7.41M	$-80.58M	$-7.56M	$-947.08K	$-7.36M	$-455.23M	$-1.76K	$-1.32K	$-1.76K	$-19.66M
High Forecast	$-12.75M	$-11.29M	$-9.99M	$-8.85M	$-4.23M	$-4.26M	$-4.22M	$-4.06M	$-3.85M	$-12.57M	$-12.51M	$-56.36M	$-11.69M	$-14.92M	$-5.17M	$-60.28M	$-58.87M	$-6.31M	$-7.41M	$-64.47M	$-7.56M	$-947.08K	$-7.36M	$-364.19M	$-1.76K	$-1.32K	$-1.76K	$-15.73M
Low Forecast	$-78.19M	$-69.23M	$-61.29M	$-54.27M	$-25.92M	$-26.13M	$-25.87M	$-20.32M	$-31.97M	$-13.06M	$-12.51M	$-84.54M	$-24.36M	$-15.26M	$-31.74M	$-90.41M	$-88.30M	$-6.31M	$-7.41M	$-96.70M	$-7.56M	$-947.08K	$-7.36M	$-546.28M	$-1.76K	$-1.32K	$-1.76K	$-23.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	7.14%	7.17%	1.21%	1.81%	15.20%	12.14%	0.98%	8.21%	27.84%	10.14%	0.44%	53366.57%	25101.21%	18738.24%	1.49%

undefined analysts predict BEAM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Beam Therapeutics's previous annual EBITDA (undefined) of $NaN.

Beam Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	9	4	5	4	8	4	5	4	4	3	4	3	14	8	9	15	10	16	8	17
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-96.09M	$-82.78M	$-84.03M	$-38.35M	$-109.58M	$-48.50M	$-55.19M	$-64.71M	$-28.12M	$-76.25M	$-201.56M	$-95.46M	$-34.45M	$-34.22M	$-30.46M
Avg Forecast	$-103.11M	$-102.82M	$-100.57M	$-99.02M	$-97.61M	$-99.14M	$-100.96M	$-99.83M	$-104.88M	$-97.51M	$-92.88M	$-74.72M	$-56.96M	$-109.49M	$-117.40M	$-79.91M	$-76.71M	$-104.06M	$-92.22M	$-85.47M	$-78.03M	$-59.64M	$-52.32M	$-458.41M	$-54.56M	$-44.94M	$-42.47M	$-20.40M
High Forecast	$-14.43M	$-14.39M	$-14.08M	$-13.86M	$-13.66M	$-13.88M	$-14.13M	$-77.45M	$-79.56M	$-13.65M	$-13.00M	$-59.78M	$-32.69M	$-15.32M	$-16.43M	$-63.93M	$-61.36M	$-104.06M	$-92.22M	$-68.38M	$-78.03M	$-59.64M	$-52.32M	$-366.73M	$-54.56M	$-44.94M	$-42.47M	$-16.32M
Low Forecast	$-247.31M	$-246.60M	$-241.22M	$-237.49M	$-234.12M	$-237.77M	$-242.15M	$-117.04M	$-123.87M	$-233.87M	$-222.78M	$-89.66M	$-72.31M	$-262.61M	$-281.57M	$-95.90M	$-92.05M	$-104.06M	$-92.22M	$-102.56M	$-78.03M	$-59.64M	$-52.32M	$-550.10M	$-54.56M	$-44.94M	$-42.47M	$-24.48M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	0.71%	1.05%	0.50%	1.05%	0.53%	0.65%	0.83%	0.47%	1.46%	0.44%	1.75%	0.77%	0.81%	1.49%

Beam Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BEAM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Beam Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	9	4	5	4	8	4	5	4	4	3	4	3	14	8	9	15	10	16	8	17
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$25.41M	$24.66M	$23.49M	$22.68M	$21.82M	$24.06M	$19.25M	$17.77M	$15.77M	$13.40M	$10.27M	$8.35M	$7.50M	$6.94M	$6.81M
Avg Forecast	$20.29B	$17.97B	$15.91B	$14.09B	$6.73B	$6.78B	$6.71B	$6.70B	$7.55B	$6.90B	$6.74B	$8.13B	$8.88B	$8.13B	$8.24B	$7.42B	$6.05B	$3.40B	$3.99B	$23.77M	$4.07B	$510.24M	$3.96B	$951.27K	$951.27K	$713.45K	$951.27K	$2.15M
High Forecast	$42.12B	$37.30B	$33.02B	$29.24B	$13.96B	$14.08B	$13.94B	$10.95B	$17.22B	$7.03B	$6.74B	$8.13B	$13.12B	$8.22B	$17.10B	$15.41B	$12.55B	$3.40B	$3.99B	$28.52M	$4.07B	$510.24M	$3.96B	$951.27K	$951.27K	$713.45K	$951.27K	$2.57M
Low Forecast	$6.87B	$6.08B	$5.38B	$4.77B	$2.28B	$2.30B	$2.27B	$2.19B	$2.07B	$6.77B	$6.74B	$8.13B	$6.30B	$8.04B	$2.79B	$2.51B	$2.05B	$3.40B	$3.99B	$19.01M	$4.07B	$510.24M	$3.96B	$951.27K	$951.27K	$713.45K	$951.27K	$1.72M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.81%	0.00%	0.03%	0.00%	10.80%	8.78%	10.52%	7.29%	3.18%

Beam Therapeutics's average Quarter SG&A projection for Dec 23 is $8.88B, based on 8 Wall Street analysts, with a range of $6.30B to $13.12B. The forecast indicates a 34853.35% rise compared to BEAM last annual SG&A of $25.41M (Sep 23).

Beam Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	4	4	4	4	3	3	3	5	9	4	5	4	8	4	5	4	4	3	4	3	14	8	9	15	10	16	8	17
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.22	$-1.08	$-1.16	$-0.54	$-1.56	$-0.69	$-0.80	$-0.95	$-0.42	$-1.23	$-3.35	$-1.59	$-0.69	$-0.69	$-1.03
Avg Forecast	$-1.25	$-1.25	$-1.22	$-1.20	$-1.18	$-1.20	$-1.23	$-1.21	$-1.27	$-1.18	$-1.13	$-1.42	$-0.69	$-1.33	$-1.42	$-1.32	$-1.36	$-1.26	$-1.12	$-0.89	$-0.95	$-0.72	$-0.64	$-0.74	$-0.66	$-0.55	$-0.52	$-0.51
High Forecast	$-0.18	$-0.17	$-0.17	$-0.17	$-0.17	$-0.17	$-0.17	$-0.94	$-0.97	$-0.17	$-0.16	$-0.20	$-0.40	$-0.19	$-0.20	$-0.18	$-0.19	$-1.26	$-1.12	$-0.89	$-0.95	$-0.72	$-0.64	$-0.74	$-0.66	$-0.55	$-0.52	$-0.51
Low Forecast	$-3.00	$-2.99	$-2.93	$-2.88	$-2.84	$-2.89	$-2.94	$-1.42	$-1.50	$-2.84	$-2.70	$-3.39	$-0.88	$-3.19	$-3.42	$-3.17	$-3.26	$-1.26	$-1.12	$-0.89	$-0.95	$-0.72	$-0.64	$-0.74	$-0.66	$-0.55	$-0.52	$-0.51
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.92%	0.76%	0.88%	0.40%	1.23%	0.62%	0.90%	1.00%	0.58%	1.94%	4.53%	2.39%	1.26%	1.34%	2.04%

According to undefined Wall Street analysts, Beam Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BEAM previous annual EPS of $NaN (undefined).

Beam Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EDIT	Editas Medicine	$1.52	$10.20	571.05%	Buy
PRME	Prime Medicine	$2.91	$17.25	492.78%	Buy
SANA	Sana Bio	$1.91	$8.00	318.85%	Buy
NTLA	Intellia Therapeutics	$13.13	$53.00	303.66%	Buy
FATE	Fate Therapeutics	$1.88	$5.00	165.96%	Buy
VERV	Verve Therapeutics	$5.61	$14.00	149.55%	Buy
BEAM	Beam Therapeutics	$28.58	$55.00	92.44%	Buy
CRSP	CRISPR Therapeutics	$44.63	$77.50	73.65%	Buy
CRBU	Caribou Biosciences	$1.94	$3.00	54.64%	Buy
VRTX	Vertex Pharmaceuticals	$469.24	$533.30	13.65%	Buy
DNA	Ginkgo Bioworks	$9.61	$7.00	-27.16%	Buy

BEAM Forecast FAQ

Is Beam Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, Beam Therapeutics (BEAM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of BEAM's total ratings.

What is BEAM's price target?

Beam Therapeutics (BEAM) average price target is $55 with a range of $39 to $69, implying a 89.59% from its last price of $29.01. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Beam Therapeutics stock go up soon?

According to Wall Street analysts' prediction for BEAM stock, the company can go up by 89.59% (from the last price of $29.01 to the average price target of $55), up by 137.85% based on the highest stock price target, and up by 34.44% based on the lowest stock price target.

Can Beam Therapeutics stock reach $40?

BEAM's average twelve months analyst stock price target of $55 supports the claim that Beam Therapeutics can reach $40 in the near future.

What are Beam Therapeutics's analysts' financial forecasts?

Beam Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $56.61M (high $111.27M, low $18.99M), average EBITDA is $-49.98M (high $-16.767M, low $-98.233M), average net income is $-398M (high $-119M, low $-831M), average SG&A $26.93B (high $52.92B, low $9.03B), and average EPS is $-4.824 (high $-1.445, low $-10.085). BEAM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $143.5M (high $297.87M, low $48.57M), average EBITDA is $-127M (high $-42.877M, low $-263M), average net income is $-406M (high $-56.757M, low $-973M), average SG&A $68.26B (high $141.68B, low $23.1B), and average EPS is $-4.921 (high $-0.689, low $-11.802).

Did the BEAM's actual financial results beat the analysts' financial forecasts?

Based on Beam Therapeutics's last annual report (Dec 2022), the company's revenue was $60.92M, which missed the average analysts forecast of $72.4M by -15.85%. Apple's EBITDA was $-401M, beating the average prediction of $-168M by 139.14%. The company's net income was $-264M, missing the average estimation of $-358M by -26.46%. Apple's SG&A was $87.8M, missing the average forecast of $13.46B by -99.35%. Lastly, the company's EPS was $-3.76, missing the average prediction of $-4.633 by -18.85%. In terms of the last quarterly report (Sep 2023), Beam Therapeutics's revenue was $17.19M, beating the average analysts' forecast of $17.09M by 0.61%. The company's EBITDA was $-108M, beating the average prediction of $-15.086M by 614.21%. Beam Therapeutics's net income was $-96.088M, missing the average estimation of $-109M by -12.24%. The company's SG&A was $25.41M, missing the average forecast of $8.13B by -99.69%. Lastly, the company's EPS was $-1.22, missing the average prediction of $-1.329 by -8.18%